Zacks Investment Research upgraded shares of Regulus Therapeutics (NASDAQ:RGLS) from a hold rating to a buy rating in a report published on Thursday morning. Zacks Investment Research currently has $1.25 target price on the biopharmaceutical company’s stock.
According to Zacks, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. “
Several other equities research analysts also recently weighed in on RGLS. Needham & Company LLC reaffirmed a hold rating on shares of Regulus Therapeutics in a report on Tuesday, November 14th. Wedbush reaffirmed an outperform rating and set a $4.00 price target on shares of Regulus Therapeutics in a report on Monday, December 11th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus price target of $2.46.
A number of large investors have recently added to or reduced their stakes in the business. GSA Capital Partners LLP raised its position in Regulus Therapeutics by 44.8% in the third quarter. GSA Capital Partners LLP now owns 203,815 shares of the biopharmaceutical company’s stock worth $255,000 after acquiring an additional 63,100 shares in the last quarter. South Dakota Investment Council raised its position in Regulus Therapeutics by 37.1% in the third quarter. South Dakota Investment Council now owns 1,820,027 shares of the biopharmaceutical company’s stock worth $2,275,000 after acquiring an additional 492,969 shares in the last quarter. Candriam Luxembourg S.C.A. purchased a new position in Regulus Therapeutics in the third quarter worth $750,000. NEA Management Company LLC purchased a new position in Regulus Therapeutics in the third quarter worth $13,737,000. Finally, Victory Capital Management Inc. purchased a new position in Regulus Therapeutics in the third quarter worth $347,000. Hedge funds and other institutional investors own 59.39% of the company’s stock.
About Regulus Therapeutics
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.